Enbrel News and Research

RSS
Physicians increase prescription of new biologics

Physicians increase prescription of new biologics

Abbott/Eisai's Humira termed as  most efficacious therapy for psoriasis

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Study shows CEL-2000 vaccine blocks RA progression in mice

Study shows CEL-2000 vaccine blocks RA progression in mice

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

New biomarker may predict treatment outcomes in RA patients

New biomarker may predict treatment outcomes in RA patients

Prescription drugs prove effective in managing moderate to severe psoriasis

Prescription drugs prove effective in managing moderate to severe psoriasis

UCB's Cimzia gains market share of Centocor's Simponi

UCB's Cimzia gains market share of Centocor's Simponi

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics' three drug candidates granted U.S. patents

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Dermatologists express strong interest in Stelara, despite concerns

Dermatologists express strong interest in Stelara, despite concerns

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

TNF-alpha inhibitors ranked top for reducing biologics spend

TNF-alpha inhibitors ranked top for reducing biologics spend

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

RA patients who adhere to their prescription drug regimen have better outcome: Study

RA patients who adhere to their prescription drug regimen have better outcome: Study